Live Breaking News & Updates on Portuguese Health Authority
Stay updated with breaking news from Portuguese health authority. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Somai GMP Facility Somai GMP Facility LISBON, Portugal, Sept. 01, 2023 (GLOBE NEWSWIRE) SOMAÍ Pharmaceuticals Unipessoal LDA (the “Company” or “SOMAÍ”), the largest European pharmaceutical cannabis product manufacturer, is pleased to announce that it has received authorisation for its facility located in Lisbon, Portugal from the Portuguese Health Authority INFRAMED (authorisation number 42/V01 de 25/08/2023). This authorisation permits the Company to manufacture, import, and export medicinal ....
LISBON, Portugal, Sept. 01, 2023 (GLOBE NEWSWIRE) SOMAÍ Pharmaceuticals Unipessoal LDA (the “Company” or “SOMAÍ”), the largest European pharmaceutical. ....
Somaí Pharmaceuticals Receives Eu-Gmp Certification And Raises €5 Million menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.
European pharmaceutical cannabis product manufacturer SOMAÍ Pharmaceuticals Unipessoal LDA received authorization for its facility in Lisbon, Portugal, from the Portuguese Health Authority INFRAMED. Why It Matters This authorization allows the company to produce, import, and export medicinal cannabis products to numerous global markets. ....
At the time of the first wave of the COVID-19 pandemic, patients with cancer were considered to be at high risk of serious illness and had a higher exposure risk since they needed frequent and nondeferrable hospital visits. Serological tests were not routinely used, and seroprevalence in this population was unknown.
A single-center, cross-sectional study was developed to determine the seroprevalence of anti-SARS-CoV-2 antibodies (Abs) in patients with cancer undergoing systemic antineoplastic treatment. One hundred patients were consecutively recruited in a two-week period (6th-20th May 2020), and serum samples were tested for the presence of immunoglobulin M (IgM) and immunoglobulin G (IgG) Abs directed against both spike (S) and nucleocapsid (N) SARS-CoV-2 proteins in two distinct time points (at recruitment and 4-8 weeks later). IgG-positive results were subject to confirmation, in the same serum sample, using two distinct assays.